KITE PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 700
- Registration Number
- NCT05041309
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 114
- Registration Number
- NCT04989803
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
- Conditions
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 90
- Registration Number
- NCT04880434
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 15
- Registration Number
- NCT04789408
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇫🇷Institut Paoli-Calmettes, Marseille, France
🇺🇸Stanford Cancer Center, Stanford, California, United States
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 6
- Registration Number
- NCT04314843
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York, United States
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
- Conditions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT04162756
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 40
- Registration Number
- NCT04155749
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 16
- Registration Number
- NCT04025216
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 27
- Registration Number
- NCT04002401
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 42
- Registration Number
- NCT03761056
- Locations
- 🇺🇸
Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷Hopital Saint Louis, Paris, France